Quantcast

Latest Rofecoxib Stories

a2845b17ec1dac4006d278cf4005fc051
2008-03-31 00:35:00

Vytorin, a controversial new drug that fights cholesterol, might not be living up to initial expectations for battling heart disease, according to a leading panel of experts who are suggesting patients stick with statins. A study known as Enhance released full results Sunday that found the combination drug failed to show it worked any better than a less-expensive generic statin at reversing heart disease. These results mirrored ones released in January by the drug's makers Merck & Co and...

2008-02-12 15:00:08

Dr. Alastair J.J. Wood, drug development authority, frequent advisor to the Food and Drug Administration (FDA) and former Assistant Vice Chancellor for Research at Vanderbilt University, was recently named to the Board of Directors of the Critical Path Institute. Wood, whose numerous honors include membership to the Institute of Medicine of the National Academies of Science, is widely considered a leading international expert on drug safety and drug development. "Dr. Wood brings...

6a175ee0428b07774aea0690a629e5fe1
2008-01-24 15:20:00

BUFFALO, N.Y. -- Celebrex, a popular arthritis drug that blocks pain by inhibiting an enzyme known as COX-2, has been shown in laboratory studies to induce arrhythmia, or irregular beating of the heart, via a novel pathway unrelated to its COX-2 inhibition. University at Buffalo researchers discovered this unexpected finding while conducting basic research on potassium channels. They found that low concentrations of the drug, corresponding to a standard prescription, reduced the heart rate...

2007-09-16 06:00:00

By Wagenitz, Andreas Mueller, Edgar A; Frentzel, Adrian; Cambon, Nathalie Key words: Analgesia - Diclofenac - Non-inferiority analysis - NSAID - Osteoarthritis - Sustained-release ABSTRACT Objective: To compare the analgesic efficacy and tolerability of a sustained-release pellet formulation of diclofenac (Olfen-100 SR Depocaps, SR-CAP, Mepha Ltd, Aesch, Switzerland) with the standard reference formulation (Voltaren retard 100, SR-TAB, Novartis Pharma AG, Basel, Switzerland), both...

80ec3d4bc48aac4c78c637710e0f358c1
2007-05-23 14:30:00

How does a drug go from blockbuster to bust? How can big safety issues go undetected in medicines taken by millions of people for many years, as happened this week with the diabetes pill Avandia and a few years ago with the painkiller Vioxx? Or with devices like drug-coated stents, which came under a cloud last year after 6 million heart patients had already received them? All roads - and fingers this week - point to the U.S. Food and Drug Administration. From a company's labs to a consumer's...

2007-04-04 03:00:08

By Saudan, M; Saudan, P; Perneger, T; Riand, N; Et al We examined whether a selective cyclo-oxygenase-2 (COX-2) inhibitor (celecoxib) was as effective as a non-selective inhibitor (ibuprofen) for the prevention of heterotopic ossification following total hip replacement. A total of 250 patients were randomised to receive celecoxib (200 mg b/d) or ibuprofen (400 mg t.d.s) for ten days after surgery. Anteroposterior radiographs of the pelvis were examined for heterotopic ossification three...

2006-11-13 12:00:18

U.S. firm Merck said Monday its new COX 2 painkiller -- in the same class as Vioxx -- has a cardiac risk similar to Novartis' Voltaren. According to data from a large patient trial released Monday, Merck said its new arthritis treatment Arcoxia (etoricoxib), carries a comparable risk of heart attack and other cardiovascular events, compared to Voltaren (diclofenac), but showed a lower risk of gastrointestinal problems, like bleeding ulcers. However, Merck said the data also revealed that...

2006-08-30 12:57:04

NEW YORK (Reuters) - A federal judge overturned a $50 million award handed down by a jury against Merck & Co. Inc. earlier this month in a case of a former FBI agent who had blamed the withdrawn painkiller Vioxx for his heart attack. In a written ruling, U.S. District Court Judge Eldon Fallon did not dispute the jury's finding that Merck knowingly misrepresented or failed to disclose a material fact regarding Vioxx safety to the plaintiff's physician, but ordered a new trial to...

2006-08-30 12:38:47

NEW YORK (Reuters) - A federal judge overturned a $50 million award handed down by jury against Merck & Co. earlier this month in a case of a former FBI agent who had blamed the withdrawn painkiller Vioxx for his heart attack, the Wall Street Journal reported on its web site on Wednesday. Merck did not immediately return phone calls seeking comment. A New Orleans jury in the federal trial had found that Merck knowingly misrepresented or failed to disclose a material fact...

2006-08-23 09:20:00

CHICAGO -- Merck & Co. on Wednesday said the experimental arthritis drug Arcoxia, in a study, met its main goal of causing no more blood clot-related heart attacks than a standard treatment, but more patients taking Arcoxia withdrew from the trial due to serious side effects. The trial pitted Arcoxia, the planned successor to Vioxx, against diclofenac, a widely used non-steroidal anti-inflammatory drug, among patients with osteoarthritis and rheumatoid arthritis. Vioxx was pulled off the...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related